All In Biotech

Drug Trial Radar · NCT00549770

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Aug 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,334 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,334

Actual

Start

Sep 2007

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 26, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to placebo.

Conditions

  • Hypertension

Interventions

  • LCZ696Drug

  • ValsartanDrug

  • AHU377Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)Time frame: baseline, week 8

Locations

182 sites in 18 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Muscle Shoals, Alabama

  • Novartis Investigative Site

    Chandler, Arizona

  • Novartis Investigative Site

    Buena Park, California

  • Novartis Investigative Site

    Fair Oaks, California

  • Novartis Investigative Site

    Long Beach, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Orangevale, California

  • Novartis Investigative Site

    Santa Ana, California

  • Novartis Investigative Site

    Stockton, California

  • Novartis Investigative Site

    Tustin, California

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Pembroke Pines, Florida

  • Novartis Investigative Site

    Pembroke Pines, Florida

  • Novartis Investigative Site

    Pensacola, Florida

  • Novartis Investigative Site

    Augusta, Georgia

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Peoria, Illinois

  • Novartis Investigative Site

    Baton Rouge, Louisiana

  • Novartis Investigative Site

    Metairie, Louisiana

  • Novartis Investigative Site

    Chelsea, Michigan

  • Novartis Investigative Site

    Royal Oak, Michigan

  • Novartis Investigative Site

    Brooklyn Center, Minnesota

  • Novartis Investigative Site

    City of Saint Peters, Missouri

  • Novartis Investigative Site

    Toms River, New Jersey

  • Novartis Investigative Site

    Trenton, New Jersey

  • Novartis Investigative Site

    Cincinnati, Ohio

  • Novartis Investigative Site

    Cincinnati, Ohio

  • Novartis Investigative Site

    Oklahoma City, Oklahoma

  • Novartis Investigative Site

    Simpsonville, South Carolina

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Lake Jackson, Texas

  • Novartis Investigative Site

    Richmond, Virginia

  • Novartis Investigative Site

    Charleston, West Virginia

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.